Turning molecular interactions into actionable insights for drug discovery and translational research
In biomedical research, the challenge is no longer generating data but understanding what that data means. High-throughput technologies now generate detailed molecular readouts across diseases, treatments, and patients. Yet, translating those observations into clear biological mechanisms, actionable biomarkers and confident therapeutic hypotheses remains a major bottleneck.
In our recent webinar, “Unlocking Translational Research with Curated Molecular Interaction Databases”, Matt Wampole (Director, Solution Consulting, Clarivate), joined Alex Ishkin (Lead Consultant) and Martí Bernardo-Faura (Manager, Senior Consultant) from Clarivate’s Discovery & Translational Science (DTS) Consulting team to explore how curated molecular interaction knowledge can help bridge this gap. The discussion showed how MetaBase supports researchers to move beyond descriptive omics analysis toward a deeper understanding of disease biology, drug response, and translational decision-making.
Why molecular context matters
One of the major obstacles faced by translational researchers is the fragmentation of biological knowledge across thousands of publications and databases.
As Alex Ishkin highlighted, omics datasets alone can show which genes, proteins or post-translational modifications are affected in disease, but they do not explain which mechanisms are driving those changes, which pathways are most relevant, or whether a signal is likely to translate into a meaningful therapeutic opportunity.
Conversely, molecular interactions are highly context specific. The likelihood of two molecular entities interacting is shaped by the cellular context, including cell type, temporal dynamics, subcellular location, and the local microenvironment. Therefore, integrating experimental observations with richly contextualized molecular interaction data is critical to transform data into mechanistic insight.
This is particularly important in drug discovery and translational research, where teams often need to answer complex questions: What molecular mechanisms drive disease progression? Which targets are the most promising? How does a therapy affect key pathways? Which biomarkers inform response, resistance, or patient stratification?
Answering these questions requires more than statistics. It requires a trusted biological framework that connects genes, proteins, RNAs, compounds, pathways, diseases and phenotypes with supporting evidence.
From associations to mechanisms
Many biological resources provide useful associations, but mechanistic interpretation requires richer detail: whether interactions are direct or indirect, activating or inhibitory, and supported by strong experimental evidence.
This distinction is critical for inferring causality. A simple interaction network may help identify genes close to a disease process, but a richer model is needed to understand directionality, biological effect, and mechanism of action. During the webinar, the speakers emphasized that these details are critical for moving from lists of molecular changes to interpretable models of how biological systems behave.
Curated molecular interaction databases such as MetaBase are designed to support this type of reasoning. By capturing biological relationships with contextual annotations — including direction, effect, mechanism and confidence — they provide a foundation for systems biology analyses that help researchers reconstruct mechanisms, prioritize hypotheses and interpret omics data in a more biologically meaningful way.
Connecting evidence across discovery and translational research
Curated molecular interaction knowledge supports multiple stages of R&D. In early discovery, it can inform target identification and prioritization; in translational research, it can link molecular signatures to biomarkers, patient subgroups or treatment response; and in mechanism-of-action studies, it can clarify downstream drug effects. It can also reveal shared pathways and drivers across diseases, supporting drug repurposing, indication expansion and complementary drug combinations.
As Alex pointed out, “MetaBase is our primary knowledge base for systems biology, with information from around 3,500 different scientific journals, extracted by an expert curator team using controlled vocabulary and a multi-tiered validation system. The database is updated quarterly, ensuring that our knowledge remains consistent and up to date, and it can serve as a good basis for our systems biology workflows”.
MetaBase brings together multiple layers of evidence, including molecular interactions, disease associations, pathways, toxicology-related information and biomarker knowledge to provide a more complete view of complex biological systems. This helps teams interpret multi-omics data in context by linking molecular changes to pathways, regulators and disease biology, supporting more transparent and evidence-based decisions.
A practical example: understanding drug sensitivity and resistance
The webinar illustrated how MetaBase can be applied in real-world translational research. Martí Bernardo-Faura presented a case study involving a clinical-stage oncology biotechnology company developing a kinase inhibitor. The objective was to better understand mechanisms of drug sensitivity and resistance across cancer types and to identify biomarkers that could support patient stratification.
The project integrated complex data layers, including proteomics, kinase activity, phosphoproteomics and molecular interaction networks. Using MetaBase, we expanded interactions with phosphosite information and applied causal regulation methods to reconstruct mechanisms associated with treatment response.
This approach identified candidate biomarkers and key regulatory pathways associated with both sensitivity and resistance, illustrating how curated molecular interaction knowledge can help transform complex experimental data into interpretable translational insight.
Why methods and expertise still matter
A strong knowledge base is essential, but method selection and scientific expertise remain critical. As Martí noted, “different biological questions require different computational approaches, and the choice of algorithms can strongly influence the results”.
This is why Clarivate combines curated biological knowledge with systems biology expertise, multi-omics analysis capabilities and ongoing evaluation of computational methods. Initiatives such as the Computational Biology for Drug Discovery (CBDD) consortium and the Algorithm Benchmarking Consortium (ABC) support method selection, reproducibility and confidence in the resulting insights.
For translational teams, this combination is particularly important. The goal is to generate hypotheses that are biologically plausible, evidence-backed, and actionable. Curated data, robust algorithms, and expert interpretation work together to reduce ambiguity and support more confident R&D decisions.
What’s next: upcoming webinar sessions
This webinar was the first in a broader series exploring MetaBase and its applications across life sciences. Join us for the second and third episodes on October 8th and December 3rd,, where the series will continue to explore how curated biological knowledge can be applied to address real-world drug discovery and translational research challenges, highlighting practical examples, emerging methodologies and lessons learned from client engagements.
Explore how curated molecular interaction knowledge can support your research
As biomedical datasets become more complex, MetaBase helps researchers interpret omics data in biological context, connect molecular changes to disease and drug mechanisms, and turn complex evidence into clearer, more confident R&D decisions. To explore how this approach could support your R&D strategy, connect with Clarivate’s scientific and data experts.
Read more about how MetaBase supports mechanism-driven discovery and translational research.
This article was written by Aida Arcas, Senior Consultant, Discovery and Translational Science; and Martí Bernardo-Faura, Manager, Senior Consultant, Discovery and Translational Science.
